Head-to-Head trial tests drug combos for rare blood disorder

NCT ID NCT02844322

Summary

This study compared two different drug combinations for treating newly diagnosed Waldenström macroglobulinemia, a rare and slow-growing blood cancer. It involved 35 patients across multiple hospitals in China. The goal was to see which combination was better at controlling the disease and keeping it from getting worse.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for WALDENSTRÖM MACROGLOBULINEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Shuhua Yi

    Tianjin, 300020, China

Conditions

Explore the condition pages connected to this study.